ArticleFrontiers in immunology2026
Efficacy and safety of transarterial chemoembolization combined with donafenib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, retrospective propensity score-matched analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate the efficacy and safety of transarterial chemoembolization combined with donafenib and camrelizumab (TACE+D+C) versus TACE plus donafenib (TACE+D) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Methods: Patients with HCC complicated by PVTT diagnosed at two medical centers between December 2021 and July 2025 were enrolled and assigned to the TACE+D group and the TACE+D+C group. Propensity score matching (PSM) was performed at a 1:1 ratio with a caliper width of 0.2 standard deviations to balance baseline confounding factors, with 109 patients included in each group after matching. The primary endpoints were median overall survival (mOS) and median progression-free survival (mPFS), both calculated from the date of TACE completion. The secondary endpoints comprised objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Results: A total of 109 patients were enrolled in each group following PSM. In our retrospective PSM analysis, we observed that the TACE+D+C group was associated with longer mOS (15.90 vs 9.10 months, Conclusion: This retrospective PSM analysis observed a correlation between TACE+D+C triple therapy and longer survival and higher tumor response among PVTT-positive HCC patients. Given the inherent limitations of a retrospective observational design, these results cannot establish therapeutic superiority, and prospective randomized controlled trials are warranted to validate causal clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.